Analysis of response of severe eosinophilic asthmatic patients to benralizumab

• Juan Carlos Miralles-López ^[5] ; Rubén Andújar-Espinosa ^[1] ; Francisco Javier Bravo-Gutiérrez ^[6] ; Manuel Castilla-Martínez ^[7] ; Isabel Flores-Martín ^[8] ; María Loreto Alemany-Francés ^[9] ; Manuel José Pajarón-Fernández ^[2] ; Ana Mora-González ^[10] ; Sheila Cabrejos-Perotti ^[3] ; Zouhair El-Molaka ^[3] ; José Meseguer-Arce ^[1] ; María Jesús Avilés-Inglés ^[11] ; José Valverde-Molina ^[12] ; Virginia Pérez-Fernández ^[4]
  1. [1] Hospital Virgen de la Arrixaca

     Hospital Virgen de la Arrixaca

     Murcia, España

     
  2. [2] Hospital de la Vega Lorenzo Guirao

     Hospital de la Vega Lorenzo Guirao

     Cieza, España

     
  3. [3] Hospital Rafael Mendez

     Hospital Rafael Mendez

     Lorca, España

     
  4. [4] Universidad de Murcia

     Universidad de Murcia

     Murcia, España

     
  5. [5] Allergy Department, University General Hospital Reina Sofia, Murcia
  6. [6] Pulmonology Department, University General Hospital Santa Lucia, Cartagena, Murcia,
  7. [7] Pulmonology Department, University General Hospital Los Arcos, San Javier, Murcia
  8. [8] Allergy Department, University General Hospital Santa Lucia, Cartagena, Murcia
  9. [9] Pulmonology Department, University General Hospital Morales Meseguer, Murcia
  10. [10] Allergy Department, University General Hospital Morales Meseguer, Murcia
  11. [11] Pulmonology Department, University General Hospital Reina Sofia, Murcia
  12. [12] Paediatrics Department, University General Hospital Santa Lucia, Cartagena, Murcia

  Mostrar afiliaciones +
• Localización: Allergologia et immunopathologia: International journal for clinical and investigate allergology and clinical immunology, ISSN-e 1578-1267, ISSN 0301-0546, Vol. 50, Nº. 6, 2022, págs. 163-168
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Introduction: Clinical trials and real-life studies have been published showing effectiveness of benralizumab in severe eosinophilic asthmatic patients. The aim of the present study is to describe super-responders to benralizumab in a series of 79 patients who completed at least 1 year of treatment, and to compare super-responders with non super-responders.

    Methods: This is a multicenter study of the Register of Severe Asthma of the Region of Murcia (RE-ASGRAMUR) Group performed in eight hospitals under the conditions of routine clinical practice. Patients with zero exacerbations and no oral corticosteroid therapy for asthma were considered super-responders. We analyzed clinical, functional, and inflammatory parameters of selected patients.

    Results: In all, 50 of the 79 patients (63%) met the super-responder criteria. In addition, 36% of the patients (26/71) were considered as complete responders to treatment (super--responder + Asthma Control Test [ACT] ≥ 20 + forced expiratory volume in 1 s [FEV1] ≥ 80%). The super--responders were significantly older in age (P = 0.0029), had higher eosinophils count (P = 0.0423), higher proportion of nasal polyps (P = 0.036), and they had less severe disease at baseline. After 1 year of treatment, the super-responders had higher levels of ACT questionnaire (23 vs 19, P = 0.0007) and better percentage of FEV1 (83 vs 75, P = 0.0359).

    Conclusion: Almost two of the three patients treated with benralizumab were super--responders after 1 year of treatment and 36% had a complete response. Super-responders were associated with older age, higher eosinophils count, had nasal polyposis as comorbidity, and had less severe disease at baseline. This data illustrated the good real-life response of patients with severe eosinophilic asthma to the treatment with benralizumab.